Response to a Combination of Full-Dose Osimertinib and Ceritinib in a Non-Small Cell Lung Cancer Patient with EML4-ALK Rearrangement and Epidermal Growth Factor Receptor Co-Mutation

Lung cancer has been the leading cause of cancer-related deaths in both developed and developing countries, with most primary lung cancers being non-small cell lung carcinomas. Treatment for this condition is sometimes individualized. With developments in modern treatment and phase III clinical tria...

Full description

Bibliographic Details
Main Authors: Thai Hoa Thi Nguyen, Xuan Dung Pham, Khanh Linh Dao, Thanh Toan Vo
Format: Article
Language:English
Published: Karger Publishers 2021-07-01
Series:Case Reports in Oncology
Subjects:
Online Access:https://www.karger.com/Article/FullText/516404